유럽의 유전자 편집 기술 시장 : 분석 및 예측(2023-2032년)

Europe Gene Editing Technologies Market: Analysis and Forecast, 2023-2032

US $ 2,950 ￦ 4,236,000

PDF and Excel (1-3 User License)

PDF 및 Excel 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,450 ￦ 6,391,000

PDF and Excel (Global License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

유럽의 유전자 편집 기술 시장 규모는 2023년 3억 7,000만 달러에서 예측 기간 동안 27.24%의 연평균 복합 성장률(CAGR)을 나타내고, 2032년에는 32억 6,000만 달러 규모에 달할 것으로 예상됩니다. 유전자 편집 기술 시장은 주로 개인 맞춤형 의료에 대한 수요 증가로 인해 성장할 것으로 예상됩니다.

또한, 새로운 기술의 도입은 이 시장의 확장을 더욱 촉진하고 있습니다.

주요 시장 통계
예측 기간	2023-2032년
2023년 평가	3억 7,000만 달러
2032년 전망	32억 6,000만 달러
CAGR	27.24%

유럽의 유전자 편집 기술 시장은 개인 맞춤형 의료에 대한 수요 증가와 첨단 기술 도입에 힘입어 괄목할 만한 성장세를 보이고 있습니다. 유전자 편집 기술은 환자 개개인에 맞게 의료 절차를 조정하고 보다 효과적인 치료법을 제공할 수 있는 가능성으로 각광을 받고 있습니다. 또한, 새로운 유전자 편집 기술의 출현으로 정확성과 효율성이 향상되어 유럽에서 연구 및 임상 적용의 가치가 높아지고 있습니다. 유럽은 과학 연구, 생명공학 및 지원적인 규제 프레임워크가 잘 갖춰져 있어 유전자 편집 기술 도입에 적합한 환경을 갖추고 있습니다. 윤리적이며 책임감 있는 유전자 편집의 실천은 이 시장의 지속적인 성장을 더욱 보장하고 있습니다. 유전자 편집이 의료와 생명과학을 계속 변화시키고 있는 가운데 유럽의 유전자 편집 기술 시장은 과학 발전과 치료 혁신을 위한 유망한 기회를 제공합니다.

본 보고서는 유럽의 유전자 편집 기술 시장을 조사했으며, 시장 개요, 시장 성장에 영향을 미치는 각종 영향요인 분석, 규제 환경, 제품 벤치마킹, 기술 및 특허 동향, 시장 규모 추이 및 예측, 각종 부문별-주요 국가별 상세 분석, 주요 기업 분석 등의 정보를 정리하여 전해드립니다.

시장 분류

세분화 1 : 기술별 세분화

• CRISPR 유전자 편집 기술
• 비CRISPR 유전자 편집 기술

세분화 2: 용도별

• 농업
• 바이오 의료

세분화 3: 국가별

• 독일
• 영국
• 프랑스
• 이탈리아
• 스페인
• 스위스
• 기타

목차

주요 요약

제1장 제품 정의

제2장 시장 범위

제3장 조사 방법

제4장 시장 개요

• 시장 개요
• 시장 실적과 잠재적인 성장 시나리오
• 유전자 편집 기술의 진화
• 임상시험

제5장 업계 전망

• 규제 상황
• 유럽 법적 요건과 프레임워크
• 세계의 신속 지정
• 제품 벤치마킹
• 기술 도입 매트릭스
• 업계 동향
• 특허 분석

제6장 유럽

• 개요
• 유럽
  • 유럽의 유전자 편집 기술 시장(용도별)
  • 유럽의 유전자 편집 기술 시장(기술별)
  • 유럽의 유전자 편집 기술 시장(국가별)

제7장 기업 개요

• BRAIN Biotech AG
• Cellectis S.A.
• CRISPR Therapeutics AG
• DNA Script
• Magento, Inc.
• Merck KGaA

LSH

영문 목차

영문목차

“The Europe Gene Editing Technologies Market Expected to Reach $3.26 Billion by 2032.”

Introduction to Europe Gene Editing Technologies Market

The Europe gene editing technologies market was valued at $0.37 billion in 2023 and is anticipated to reach $3.26 billion by 2032, witnessing a CAGR of 27.24% during the forecast period 2023-2032. The gene editing technologies market is anticipated to experience growth primarily due to the rising demand for personalized medicine. Furthermore, the introduction of novel technologies has further propelled the expansion of this market.

KEY MARKET STATISTICS
Forecast Period	2023 - 2032
2023 Evaluation	$0.37 Billion
2032 Forecast	$3.26 Billion
CAGR	27.24%

Market Introduction

The European gene editing technologies market is experiencing notable growth driven by the increasing demand for personalized medicine and the introduction of advanced technologies. Gene editing techniques are gaining prominence for their potential in tailoring medical treatments to individual patients, offering more effective therapies. Additionally, the emergence of novel gene editing technologies is enhancing precision and efficiency, making them increasingly valuable for research and clinical applications in Europe. The region's robust commitment to scientific research, biotechnology, and supportive regulatory frameworks creates a conducive environment for gene editing technology adoption. Ethical and responsible gene editing practices further ensure sustainable growth in this market. As gene editing continues to transform healthcare and life sciences, the European gene editing technologies market presents promising opportunities for scientific progress and therapeutic innovation.

Market Segmentation:

Segmentation 1: by Technology

• CRISPR Gene Editing Technology
• Non-CRISPR Gene Editing Technology

Segmentation 2: by Application

• Agriculture
• Biomedical

Segmentation 3: by Country

• Germany
• U.K.
• France
• Italy
• Spain
• Switzerland
• Rest-of-Europe

How can this report add value to an organization?

Workflow/Innovation Strategy: The gene editing technologies market (by technology) has been segmented into CRISPR gene editing technology and non-CRISPR gene editing technology. Moreover, the study provides the reader with a detailed understanding of the different applications of gene editing technologies in agricultural and biomedical.

Growth/Marketing Strategy: Gene editing technologies are being used for agricultural, biomedical, and other applications. Various companies are providing gene editing products and services, which is also the key strategy for market players to excel in the current gene editing technologies market.

Competitive Strategy: Key players in the Europe gene editing technologies market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the Europe gene editing technologies market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Companies Profiled:

Table of Contents

Executive Summary

1. Product Definition

• 1.1. Inclusion and Exclusion Criteria

2. Market Scope

• 2.1. Key Questions Answered in the Report

3. Research Methodology

4. Market Overview

• 4.1. Market Overview
• 4.2. Market Footprint and Potential Growth Scenario
  • 4.2.1. Realistic Growth Scenario
  • 4.2.2. Optimistic Growth Scenario
  • 4.2.3. Pessimistic Growth Scenario
• 4.3. Evolution of Gene Editing Technologies
• 4.4. Clinical Trials

5. Industry Outlook

• 5.1. Regulatory Landscape
  • 5.1.1. Marketing Authorization
  • 5.1.2. USFDA Guidelines for BLA Submission
  • 5.1.3. Post-Authorization Regulations
• 5.2. Legal Requirements and Frameworks in Europe
  • 5.2.1. EMA Biologics License Application Process
  • 5.2.2. Centralized Procedure
  • 5.2.3. Decentralized Procedure
  • 5.2.4. Mutual-Recognition Procedure
  • 5.2.5. National Procedure
• 5.3. Expedited Regulatory Designations Around the World
• 5.4. Product Benchmarking
  • 5.4.1. Product Benchmarking (by Technology)
  • 5.4.2. Comparative Analysis
• 5.5. Technology Adoption Matrix
• 5.6. Industry Trends
  • 5.6.1. Leveraging Collaboration as a Major Key Strategies to Create Opportunities for Gene Editing Technologies
  • 5.6.2. Growing Focus on Gene Therapies
• 5.7. Patent Analysis
  • 5.7.1. Patent Analysis (by Year)
  • 5.7.2. Patent Analysis (by Technology)
  • 5.7.3. Patent Analysis (by Region)
  • 5.7.4. Patent Analysis (by Country)

6. Europe

• 6.1. Overview
• 6.2. Europe
  • 6.2.1. Europe Gene Editing Technologies Market (by Application)
  • 6.2.2. Europe Gene Editing Technologies Market (by Technology)
  • 6.2.3. Europe Gene Editing Technologies Market (by Country)
    • 6.2.3.1. Germany
      • 6.2.3.1.1. Germany Gene Editing Technologies Market (by Application)
      • 6.2.3.1.2. Germany Gene Editing Technologies Market (by Technology)
    • 6.2.3.2. U.K.
      • 6.2.3.2.1. U.K. Gene Editing Technologies Market (by Application)
      • 6.2.3.2.2. U.K. Gene Editing Technologies Market (by Technology)
    • 6.2.3.3. Switzerland
      • 6.2.3.3.1. Switzerland Gene Editing Technologies Market (by Application)
      • 6.2.3.3.2. Switzerland Gene Editing Technologies Market (by Technology)
    • 6.2.3.4. France
      • 6.2.3.4.1. France Gene Editing Technologies Market (by Application)
      • 6.2.3.4.2. France Gene Editing Technologies Market (by Technology)
    • 6.2.3.5. Spain
      • 6.2.3.5.1. Spain Gene Editing Technologies Market (by Application)
      • 6.2.3.5.2. Spain Gene Editing Technologies Market (by Technology)
    • 6.2.3.6. Italy
      • 6.2.3.6.1. Italy Gene Editing Technologies Market (by Application)
      • 6.2.3.6.2. Italy Gene Editing Technologies Market (by Technology)
    • 6.2.3.7. Rest-of-Europe
      • 6.2.3.7.1. Rest-of-Europe Gene Editing Technologies Market (by Application)
      • 6.2.3.7.2. Rest-of-Europe Gene Editing Technologies Market (by Technology)

7. Company Profiles

• 7.1. BRAIN Biotech AG
  • 7.1.1. Company Overview
  • 7.1.2. Role of BRAIN Biotech AG in the Gene Editing Technologies Market
  • 7.1.3. Major Product: Key Specifications
  • 7.1.4. Key Competitors
  • 7.1.5. Financials
  • 7.1.6. Key Insights about the Financial Health of the Company
  • 7.1.7. Analyst Perspective
• 7.2. Cellectis S.A.
  • 7.2.1. Company Overview
  • 7.2.2. Role of Cellectis S.A. in the Gene Editing Technologies Market
  • 7.2.3. Major Product: Key Specifications
  • 7.2.4. Key Competitors
  • 7.2.5. Financials
  • 7.2.6. Key Insights about the Financial Health of the Company
  • 7.2.7. Analyst Perspective
• 7.3. CRISPR Therapeutics AG
  • 7.3.1. Company Overview
  • 7.3.2. Role of CRISPR Therapeutics AG in the Gene Editing Technologies Market
  • 7.3.3. Major Product: Key Specifications
  • 7.3.4. Key Competitors
  • 7.3.5. Financials
  • 7.3.6. Key Insights about the Financial Health of the Company
  • 7.3.7. Analyst Perspective
• 7.4. DNA Script
  • 7.4.1. Company Overview
  • 7.4.2. Role of DNA Script in the Gene Editing Technologies Market
  • 7.4.3. Major Products: Key Specifications
  • 7.4.4. Key Competitors
  • 7.4.5. Analyst Perspective
• 7.5. Magento, Inc.
  • 7.5.1. Company Overview
  • 7.5.2. Role of Magento, Inc. in the Gene Editing Technologies Market
  • 7.5.3. Major Products: Key Specifications
  • 7.5.4. Key Competitors
  • 7.5.5. Analyst Perspective
• 7.6. Merck KGaA
  • 7.6.1. Company Overview
  • 7.6.2. Role of Merck KGaA in the Gene Editing Technologies Market
  • 7.6.3. Major Products: Key Specifications
  • 7.6.4. Key Competitors
  • 7.6.5. Financials
  • 7.6.6. Key Insights about the Financial Health of the Company
  • 7.6.7. Analyst Perspective

관련자료